ARTICLE
30 October 2017

PTAB Grants Rare Request For Additional Discovery In IPR

FL
Foley & Lardner

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
In Mylan v. Allergan (IPR2016-00127, Paper No. 73), the PTAB granted a rare request for discovery filed be Petitioner in response to summaries of data presented in a Patent Owner Response used to rebut obviousness.
United States Intellectual Property

In Mylan v. Allergan (IPR2016-00127, Paper No. 73), the PTAB granted a rare request for discovery filed be Petitioner in response to summaries of data presented in a Patent Owner Response used to rebut obviousness. In particular, the PTAB found that the Garmin factors for analyzing discovery requests weighed in favor of granting Petitioner's motion. However, the decision only granted the requested discovery in part, and the PTAB's reasoning as to what it granted and what it denied may be instructive in other situations.

The Patent Owner had submitted certain figures that visually depicted pharmacokinetic data designed to show the benefits of the invention so as to rebut obviousness. Certain of the figures submitted by Patent Owner lacked mean value and standard error rates, and so the Petitioner requested discovery of the underlying pharmacokinetic data so that it could properly evaluate the significance of the figures.

The PTAB granted the request for discovery of that data as to those figures. However, the Petitioner had also requested underlying pharmacokinetic data for figures in a publication submitted by Patent Owner which did contain mean value and standard error bars. In this latter case, the PTAB denied Petitioner's request for discovery, reasoning that the information presented was already sufficient to enable an assessment by Petitioner of whether the results were "significant."

The PTAB has identified five factors ("the Garmin factors") for determining whether additional discovery is in the interests of justice as required by 37 CFR 42.51(b)(2). See Garmin Int'l, Inc. v. Cuozzo Speed Techs. LLC, Case IPR2012-00001, slip op. at 6–7 (PTAB Mar. 5, 2013) (Paper 26) (informative). These factors are: (1) more than a possibility and mere allegation that something useful will be discovered; (2) requests that do not seek other party's litigation positions and the underlying basis for those positions; (3) ability to generate equivalent information by other means; (4) easily understandable instructions; and (5) requests that are not overly burdensome to answer.

This case illustrates one of the rare situations where a request for additional discovery may be granted – namely, a summary of data that does not contain sufficient information to allow a party to confirm its statistical significance.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More